CEREVEL THERAPEUTICS HLDNG I's ticker is CERE and the CUSIP is 15678U128. A total of 113 filers reported holding CEREVEL THERAPEUTICS HLDNG I in Q2 2022. The put-call ratio across all filers is 1.24 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,314,160,084 | -31.3% | 60,199,729 | 0.0% | 42.08% | +46.6% |
| Q2 2023 | $1,913,749,385 | +129310.3% | 60,199,729 | -0.7% | 28.70% | +6.6% |
| Q1 2023 | $1,478,823 | -22.7% | 60,632,356 | 0.0% | 26.92% | -35.1% |
| Q4 2022 | $1,912,345 | -99.9% | 60,632,356 | 0.0% | 41.46% | +0.2% |
| Q3 2022 | $1,713,470,000 | +6.9% | 60,632,356 | 0.0% | 41.39% | +23.4% |
| Q2 2022 | $1,603,119,000 | -24.5% | 60,632,356 | 0.0% | 33.55% | +9.2% |
| Q1 2022 | $2,122,739,000 | +8.0% | 60,632,356 | 0.0% | 30.71% | +30.7% |
| Q4 2021 | $1,965,701,000 | +9.9% | 60,632,356 | 0.0% | 23.51% | +11.4% |
| Q3 2021 | $1,788,655,000 | +15.1% | 60,632,356 | 0.0% | 21.09% | +39.1% |
| Q2 2021 | $1,553,401,000 | +86.6% | 60,632,356 | 0.0% | 15.17% | +23.8% |
| Q1 2021 | $832,482,000 | -17.2% | 60,632,356 | 0.0% | 12.25% | -67.8% |
| Q4 2020 | $1,005,284,000 | – | 60,632,356 | – | 38.09% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| BAIN CAPITAL INVESTORS LLC | 60,199,729 | $1,913,749,385 | 28.70% |
| Perceptive Advisors | 10,088,385 | $320,709,759 | 9.28% |
| Affinity Asset Advisors, LLC | 550,000 | $17,484,500 | 6.11% |
| Finepoint Capital LP | 492,545 | $15,658,006 | 5.42% |
| Paradigm Biocapital Advisors LP | 1,868,946 | $59,413,793 | 4.59% |
| BOONE CAPITAL MANAGEMENT LLC | 300,000 | $9,537,000 | 3.42% |
| Rock Springs Capital Management LP | 2,513,916 | $79,917,390 | 1.90% |
| Artal Group S.A. | 1,638,858 | $52,099 | 1.62% |
| Frazier Life Sciences Management, L.P. | 393,000 | $12,493,470 | 0.75% |
| Avidity Partners Management LP | 501,200 | $15,933,148 | 0.56% |